

Parkview Health

## Parkview Health Research Repository

---

Pharmacy

Parkview Research Center

---

2019

### **Impact of atypical antipsychotics on sedation requirements in mechanically ventilated, critically ill patients**

Michael Genday PharmD

Dustin D Linn PharmD, BCPS, BCCCP

Jim Roy PharmD, BCPS, BCCCP

Follow this and additional works at: <https://researchrepository.parkviewhealth.org/pharma>



Part of the [Pharmacy and Pharmaceutical Sciences Commons](#)

---



# Impact of atypical antipsychotics on sedation requirements in mechanically ventilated, critically ill patients

Michael Genday, PharmD; Dustin Linn, PharmD, BCPS, BCCCP; Jim Roy, PharmD, BCCCP  
Parkview Regional Medical Center  
Fort Wayne, Indiana

## BACKGROUND

- Antipsychotics have historically been given to treat delirium in the intensive care unit. Their role is controversial with more recent data reporting a lack of efficacy when used, especially in hypoactive etiologies.
- Estimated prevalence rates for delirium in the intensive care unit are as high as 50%.
- Studies have shown that prevalence rates for hypoactive delirium are as high as 80% of cases.
- Pharmacologic treatment options for delirium include antipsychotics such as haloperidol, quetiapine, olanzapine, risperidone, and ziprasidone.
- Atypical antipsychotics may be beneficial when weaning deeper sedation for extubation as it provides lighter sedation.
- Whether antipsychotics directly impact continuous sedation requirements as part of the ventilation process is unknown.

## OBJECTIVE

- To determine if atypical antipsychotics lower continuous infusion sedation requirements while also assessing risk.

## METHODS

- Retrospective chart review study**
- Inclusion:** Mechanically ventilated patients who received a dose of an atypical antipsychotic while receiving continuous sedation
- Exclusion:** Age less than 18
- Outcomes were compared over the specified date range:
  - August 1<sup>st</sup>, 2018 to August 1<sup>st</sup> 2019
- Primary Outcome:** Percent change in total sedation dose 24 hours before and after the administration of an atypical antipsychotic
- Secondary Outcomes:**
  - Change in RASS score 6 & 24 hours before and after antipsychotic administration
  - QTc > 500 ms after administration
  - Percent of subjects at RASS goal (0 or -1) before and after antipsychotic administration


## RESULTS

### Baseline Characteristics of Total Population


		(n=142)
<b>Age (Years ± SD)</b>		55.7 ± 12.7
<b>Mean ICU Length of Stay (Days, ± SD)</b>		16.1 ± 12.8
<b>Antipsychotic Duration (Days, ± SD)</b>		7.2 ± 7.7
<b>Positive CAM-ICU Prior to antipsychotic administration</b>		96/125 (76.8%)
<b>Admission Location (n, %)</b>		
	CVICU	12 (8.5%)
	Surgical ICU	47 (33.3%)
	Medical ICU	82 (57.7%)
<b>Antipsychotic Started(n, %)</b>		
	Olanzapine	31 (21.8%)
	Quetiapine	111 (78.1%)
<b>Antipsychotic Dose First Given</b>		
	Olanzapine:	
	2.5 mg	7 (22.5%)
	5 mg	15 (48.3%)
	Other (10, 25, 50 mg)	9 (29.0%)
	Quetiapine:	
	25 mg	50 (45.0%)
	50 mg	37 (33.3%)
	Other (2.5, 5, 12.5, 100 mg)	24 (21.6%)

## RESULTS

Median Percent Change in Sedation 24H Post Antipsychotic



Percent of Subjects with RASS 0 to -1 24H before and after administration (N=142)




### Ventilator Timeline (N=121)

Median Time Between:	Days [IQR]
Intubation and antipsychotic administration	5.8 [2.5-8.9]
Antipsychotic administration and extubation	3.3 [1.6-5.9]
Intubation and Extubation	9.1 [5.2-20.7]

## RESULTS

Median RASS Scores Pre and Post Administration (N=142)



## DISCUSSION & CONCLUSIONS

- Sedation in the intensive care unit is often a multi-factorial process that involves several different medications at varying times throughout an ICU stay.
- Propofol is a highly sedating medication that is often used at the beginning of an ICU stay in order to adequately sedate the patient.
- The larger decrease in propofol received after the administration of an antipsychotic argues for a relationship between antipsychotics and reduced propofol requirements.
- Almost no change in dexmedetomidine dose was found which is consistent with the current practice of using it as a primary sedative and also to wean off a ventilator.
- The slight increase in fentanyl administration may argue against a correlation between antipsychotics and reduced sedation requirements.
- When administering antipsychotics to ventilated patients, RASS scores would be expected to be closer to 0 or -1. The lack of a significant change found indicates proper sedation was used prior to antipsychotics being given.
- There was only 1 reported incidence of QTc prolongation over 500 ms.
- Considering the multi-factorial disorders of a critically ill patient, administering an antipsychotic may be correlated with a reduction in sedative doses, particularly propofol, to promote lighter sedation with a reduced risk for delirium.
- Going forward, appropriate dosing regimens, timing, and guidance on the preferred antipsychotic should be assessed.

### Limitations:

- Different doses of antipsychotics were administered making a dose related comparison to sedation requirements difficult.
- QTc was not measured frequently enough to assess adequate safety data.
- Retrospective data limits ability to assess positive behavioral changes that may have been reduced or increased with antipsychotic use.

## REFERENCES

- Devlin JW, Skrobik Y, Gélinas C, et al. Clinical practice guidelines for the prevention and management of pain, agitation/sedation, delirium, immobility, and sleep disruption in adult patients in the ICU. *Crit Care Med* 2018;46(9):e825-e873.
- ASHP therapeutic guidelines on stress ulcer prophylaxis. *Am J Health-Syst Pharm*. 1999; 56:347-79.
- Ely EW, Shintani A, Truman B, et al. Delirium as a predictor of mortality in mechanically ventilated patients in the intensive care unit. *JAMA* 2004;291:1753-1762.
- Krag M, Marker S, Perner A, et al. Pantoprazole in patients at risk for gastrointestinal bleeding in the ICU. *N Engl J Med* 2018; 379:2199-2208. DOI: 10.1056/NEJMoa1714919
- Girard TD, et al. Haloperidol and ziprasidone for treatment of delirium in critical illness. *N Engl J Med*. 2018. ePub 2018-10-22:1-12.

**Disclosure**  
The authors of this presentation have the following to disclose concerning possible financial or personal relationships with commercial entities that may have a direct or indirect interest in the subject matter of this presentation:  
Michael Genday: Nothing to disclose      Dustin Linn: Nothing to disclose      Jim Roy: Nothing to disclose